GlycoMimetics, Inc. (GLYC) Q3 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and thank you for joining the GlycoMimetics Q3 2023 earnings call. At this time, all participants are in a listen-only mode. Following management's remarks, we will hold a question and answer session. At that time, lines will be open for you. If anyone should require operator assistance, please press star, then zero on your touchtone telephone. I would now like to turn the call over to Christian Deneen Long, Company Counsel at GlycoMimetics. Please go ahead. Good morning. Today we will review our business updates and financial results for the quarter-ended September 30, 2023. The press release issued this morning is available on the company's website at glycomimetics.com. This call is being recorded. A dial-in phone replay will be available for 24 hours after the close of the call. The webcast replay will also be available for 30 days in the Investors section of the company's website. Joining me on the call today from Glycomimetics are Harit Samarjan, Chief Executive Officer, Brian Hahn, Chief Financial Officer, and Dr. Edwin Rock, Chief Medical Officer. Today's call will include forward-looking statements based on our current expectations. Forward-looking statements may include, but are not limited to, statements about the company's product candidates, UPRO-LSLN and GMI 1687, along with statements about the progress and timing of clinical trials being conducted by us or our collaborators, planned or potential regulatory agency interactions or submissions, development plans and activities, pre-launch preparations, the company's cash position and runway, and our expectations regarding data readouts from clinical trials. Such statements represent management's judgment and intention as of today and involve assumptions, risks, and uncertainties. GlycoMimeti...